GlassScriptPhysician profile
Caleb M Elmore
NPI 1013322288
$5,172.56
in general payments reported to CMS, 2019-2025
27 companies · $762 in 2025
The $762 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,428 · 2022: $1,237 · 2023: $819 · 2024: $927 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,507.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,196.70 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $497.99 | 2021-2024 | Xarelto |
| Amgen INC. | $471.32 | 2022-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $416.44 | 2022-2025 | Verquvo, Winrevair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $286.39 | 2021-2024 | Lifevest |
| Abbott Laboratories | $282.05 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $262.16 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $207.47 | 2021-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $195.67 | 2021-2024 | |
| Esperion Therapeutics, INC. | $187.65 | 2021-2022 | |
| Novo Nordisk INC | $168.80 | 2025 | Wegovy |
| United Therapeutics Corporation | $161.78 | 2021-2025 | Tyvaso |
| Pfizer INC. | $149.28 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $121.89 | 2021-2025 | Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.92 | 2023-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $77.75 | 2021 | |
| Chiesi USA, INC. | $74.44 | 2021-2023 | Kengreal |
| Kiniksa Pharmaceuticals International, Plc | $61.71 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $56.13 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Scpharmaceuticals INC. | $43.18 | 2023-2025 | |
| Convatec INC. | $30.15 | 2024 | |
| Alnylam Pharmaceuticals INC. | $28.17 | 2025 | Amvuttra |
| Medtronic, INC. | $25.76 | 2025 | Pulseselect |
| Regeneron Healthcare Solutions, INC. | $25.02 | 2024 | Evkeeza |
| Impulse Dynamics (USA) INC. | $20.48 | 2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $15.77 | 2021 | |
| Lantheus Medical Imaging, INC. | $15.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Elmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.